The Perils of Volatility: Adams Seesaws on Speculation about FDA
This article was originally published in RPM Report
Executive Summary
Adams Respiratory Therapeutics took a wild ride on June 8, with the stock plunging 10% in a matter of minutes. All because of something FDA didn't do.
You may also be interested in...
Reacting to the CATT Study: Will Makena Make a Difference?
The long awaited head-to-head trial of Avastin vs. Lucentis in macular degeneration has finally reported results. It pits a $1,500 a dose therapy against a $50, unapproved alternative that most providers think is just as good. We just had that debate over Makena. Recent comments by FDA’s top drug review official suggest there may be another connection.
Second-Guessing FDA: CMS' Expanding Regulatory Role
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.
Unapproved Drugs Become Unpaid Drugs, Effective January 1
Pharmacies and wholesalers are expressing their concern about the potential for an upcoming policy change in Part D to disrupt dispensing. Beginning Jan. 1, any medication that does not have an NDC registered with FDA will no longer be covered by the drug benefit.